These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32308266)

  • 1. Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.
    Odhar HA; Ahjel SW; Albeer AAMA; Hashim AF; Rayshan AM; Humadi SS
    Bioinformation; 2020; 16(3):236-244. PubMed ID: 32308266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
    Kandeel M; Al-Nazawi M
    Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Hosseini FS; Amanlou M
    Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
    Farhat N; Khan AU
    J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
    Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease.
    Khater I; Nassar A
    Biochem Biophys Rep; 2021 Sep; 27():101032. PubMed ID: 34099985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
    Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
    J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
    Kundu D; Selvaraj C; Singh SK; Dubey VK
    J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
    Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C
    J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
    Yuce M; Cicek E; Inan T; Dag AB; Kurkcuoglu O; Sungur FA
    Proteins; 2021 Nov; 89(11):1425-1441. PubMed ID: 34169568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2.
    Chandel V; Sharma PP; Raj S; Choudhari R; Rathi B; Kumar D
    J Biomol Struct Dyn; 2022 Jan; 40(1):249-262. PubMed ID: 32838660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.